Litkowski Leonard, Greenspan David C
Dentsply International, York, PA, USA.
J Clin Dent. 2010;21(3):77-81.
NovaMin is technically described as amorphous sodium calcium phosphosilicate, and has been shown in laboratory studies to rapidly occlude dentin tubules through the deposition of particles that react to form a protective layer, similar to bone mineral, on the dentin surface. NovaMin was originally developed as a bone regenerative material and is highly biocompatible. The objective of this pilot study was to compare the safety and effectiveness of two prototype formulations containing 2.5% and 7.5% w/w NovaMin to a placebo dentifrice for the treatment of dentin hypersensitivity.
This was a randomized, double-blind, placebo-controlled pilot study. Sixty-six subjects with a confirmed diagnosis of dentin hypersensitivity were randomized to one of three treatments: 2.5% NovaMin, 7.5% NovaMin, or placebo. Two standard test stimuli, tactile and thermal air, were applied to sensitive cervical dentin surfaces. Subjects recorded the intensity of sensitivity in response to each stimulus on a visual analog scale at baseline, and after two, four, and eight weeks of twice-daily product use. Oral soft tissues were examined and spontaneous reports of adverse experiences were also monitored.
Comparison of the mean change from baseline among the three treatment groups indicated a meaningful reduction in sensitivity scores in the 7.5% group that was significant compared to reductions observed in the placebo control group at all time points.
The results of this study are supportive of the incorporation of NovaMin into products intended for the reduction of dentin hypersensitivity.
NovaMin在技术上被描述为无定形钠钙磷硅酸盐，实验室研究表明，它可通过沉积颗粒快速封闭牙本质小管，这些颗粒发生反应，在牙本质表面形成一层类似于骨矿物质的保护层。NovaMin最初是作为一种骨再生材料开发的，具有高度的生物相容性。这项初步研究的目的是比较两种分别含有2.5%和7.5%（重量/重量）NovaMin的原型配方与一种安慰剂牙膏治疗牙本质过敏的安全性和有效性。
这是一项随机、双盲、安慰剂对照的初步研究。66名确诊为牙本质过敏的受试者被随机分为三种治疗组之一：2.5%NovaMin组、7.5%NovaMin组或安慰剂组。对敏感的颈部牙本质表面施加两种标准测试刺激，即触觉刺激和热空气刺激。受试者在基线时以及每天使用两次产品两周、四周和八周后，以视觉模拟量表记录对每种刺激的敏感程度。检查口腔软组织，并监测不良经历的自发报告。
三个治疗组与基线相比的平均变化比较表明，7.5%组的敏感评分有显著降低，在所有时间点与安慰剂对照组相比均具有统计学意义。
本研究结果支持将NovaMin纳入旨在降低牙本质过敏的产品中。
